rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Atossa Therapeutics, Inc.

ATOS · Nasdaq

Health CareBiotechnologyNot moving yet

ATOS stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 26.8% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 50
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
1
Institutions holding
32 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$9,534Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Roger Marshall House: U.S. House ClerkKS01boughtdependent child$1k–$15k25 Oct 2017filed 6 Aug 2018

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders32+2 on the quarter
New · exited7 · 5
Reported value$2.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026361,747$698K+12,651+3.6%
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 2026258,234$498K+3,100+1.2%
BlackRock, Inc.added · filed 7 Aug 2026164,358$317K+31,189+23.4%
Aster Capital Management (DIFC) Ltdnew · filed 13 Aug 2026144,853$120K+144,853
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026132,043$255K+23,036+21.1%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202692,382$178K-4,679−4.8%
UBS Group AGreduced · filed 13 Aug 202682,620$159K-9,414−10.2%
JANE STREET GROUP, LLCnew · filed 14 Aug 202656,602$109K+56,602
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202652,583$101K+348+0.7%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 202646,508$90K-20,231−30.3%
31 Mar 2023 – 30 Jun 2026
325272Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

H. Lawrence Remmel Company insiderDirector · last 12 May 20265 · 0
Jonathan Finn Company insiderDirector · last 12 May 20261 · 0
Richard I. Steinhart Company insiderDirector · last 12 May 20260 · 0
Shu-Chih Chen Company insiderDirector · last 12 May 20263 · 1
Stephen J. Galli Company insiderDirector · last 12 May 20260 · 0
Tessa Cigler Company insiderDirector · last 12 May 20260 · 0
Steven C. Quay Company insiderPresident & CEO · last 27 Mar 20264 · 1
Mark James Daniel Company insiderChief Financial Officer · last 26 Mar 20260 · 0
Heather Rees Company insiderChief Financial Officer · last 15 May 20250 · 0
Gregory L. Weaver Company insiderFormer EVP, CFO, & Director · last 15 Nov 20232 · 2
Kyle Guse Company insiderCFO, Gen Counsel and Secretary · last 2 Mar 20231 · 0
Roger Marshall HouseKS01 · last 25 Oct 20171 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-94.4%
Share count trendFY 2025 · to 17 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$41.3M
Free cash flowFY 2025 · to 31 Dec 2025−$29.8M

Analyst forecasts

No analyst forecasts yet.